BioSpace News Archive

Junshi Biosciences (HKEX: 1877; SSE: 688180), announced today that the National Medical Products Administration (the “NMPA”) has accepted the company’s supplemental New Drug Application (“sNDA”) for toripalimab in combination with chemotherapy as the first-line treatment of patients with treatment-naive advanced or metastatic non-small cell lung cancer (“NSCLC”) with no EGFR or ALK tumor aberrations.

Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors are defined as medications that have been developed to lower cholesterol levels.

Pomalidomide is a cancer medicine used in the treatment of multiple myeloma (a cancer of the bone marrow). It is also used in combination with bortezomib (i.e. cancer medicine) and dexamethasone (an anti-inflammatory medicine) in geriatric patients who have received at least one treatment including lenalidomide.

The sinusitis drugs market has been expected to experience significant growth opportunities in the forthcoming years.

MediciNova, Inc. and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND including an analysis of baseline characteristics from the initial patients enrolled in COURAGE-ALS.

TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63 rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.

Genetic Technologies Limited confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.

BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the presentation of additional analyses from the Phase 3 portion of the PROTECTIVE-2 trial evaluating the combination of plinabulin and pegfilgrastim for the prevention of chemotherapy-induced neutropenia (CIN) in breast cancer patients at the 2021 San Antonio Breast Cancer Symposium.

Candel Therapeutics, Inc. (Nasdaq: CADL), today announced a collaboration with Partnership for Accelerating Cancer Therapies (PACT) and the Cancer Immune Monitoring and Analysis Centers – Cancer Immunologic Data Commons (CIMAC-CIDC) to profile the biomarker response to a combination of CAN-2409 + valacyclovir in combination with anti-PD-1 and PD-L1 immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC).